EUCTR2012-001622-10-PL进行中（未招募）不适用
A randomised, placebo-controlled, double-blind, parallel groups, multinational, multicentre trial assessing the effect of barusiban administered subcutaneously on the day of transfer on implantation and pregnancy rates in IVF/ICSI patients - BASIC
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •- Women aged 18-37 years
- •- Women who have undergone 2-4 previous fresh IVF/ICSI cycles that all resulted in a negative ßhCG test, despite transfer of at least one embryo/blastocyst of good quality
- •- Women who have in the current controlled ovarian stimulation cycle for IVF/ICSI followed the long GnRH agonist or GnRH antagonist protocol, received hCG for triggering of final follicular maturation and have undergone oocyte retrieval for IVF/ICSI with the purpose of fresh transfer
- •- Retrieval of at least 6 oocytes in the current controlled ovarian stimulation cycle
- •- Subjects should have at least one embryo of good quality available for transfer on day 3, or one expanded or hatching/hatched blastocyst available for transfer on day 5
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 340
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- A total of 6 or more controlled ovarian stimulation cycles for IVF/ICSI
- •- Abnormal karyotype
- •- Uterine pathology or hydrosalpinx
- •- Diagnosed with acquired or congenital thrombophilia disease
研究者
相似试验
进行中（未招募）
1 期
Clinical study to evaluate the treatment effect and safety of BAY1817080 in patients with overactive bladder (OAB)MedDRA version: 23.1Level: LLTClassification code 10059617Term: Overactive bladderSystem Organ Class: 100000004857Overactive BladderEUCTR2019-002575-34-GBBayer AG100
进行中（未招募）
不适用
A randomised, placebo-controlled, double-blind, parallel groups, multinational, multicentre trial assessing the effect of barusiban administered subcutaneously on the day of transfer on implantation and pregnancy rates in IVF/ICSI patientsInfertility femaleMedDRA version: 14.1Level: PTClassification code 10021928Term: Infertility femaleSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2012-001622-10-BEFerring Pharmaceuticals A/S340
进行中（未招募）
不适用
A randomised, placebo-controlled, double-blind, parallel groups, multinational, multicentre trial assessing the effect of barusiban administered subcutaneously on the day of transfer on implantation and pregnancy rates in IVF/ICSI patientsInfertility femaleMedDRA version: 14.1Level: PTClassification code 10021928Term: Infertility femaleSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2012-001622-10-CZFerring Pharmaceuticals A/S340
进行中（未招募）
1 期
A randomised, placebo-controlled, double-blind, parallel groups, multinational, multicentre trial assessing the effect of barusiban administered subcutaneously on the day of transfer on implantation and pregnancy rates in IVF/ICSI patientsInfertility femaleMedDRA version: 14.1Level: PTClassification code 10021928Term: Infertility femaleSystem Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2012-001622-10-ESFerring Pharmaceuticals A/S255
进行中（未招募）
不适用
A randomised, placebo controlled, double-blind, parallel group, international study to evaluate the safety and efficacy of rituximab (MabThera/Rituxan) in combination with methotrexate, compared to methotrexate monotherapy, in patients with active rheumatoid arthritis.EUCTR2005-002392-32-SIF. Hoffmann-La Roche Ltd.500